Febit Slashes Headcount, Kills Sequence Capture, Expression Offerings in Favor of miRNA Play

The cuts were necessary to take advantage of a "window of opportunity" in miRNA discovery that could enable the firm to enter the molecular diagnostics market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.